Methyl-3,5-diisopropylphenylaether | 92100-77-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Methyl-3,5-diisopropylphenylaether
• 英文别名: 1-Methoxy-3,5-di(propan-2-yl)benzene
• CAS: 92100-77-1
• 化学式: C₁₃H₂₀O
• 分子量: 192.301
• InChiKey: DIMVOGCDFXHKOE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
  申请人：PharmAkea, Inc.

  公开号：US10570094B2

  公开（公告）日：2020-02-25

  Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

  本文描述了作为 LOXL2 抑制剂的化合物、制造此类化合物的方法、包含此类化合物的药物组合物和药物，以及使用此类化合物治疗与 LOXL2 活性相关的病症、疾病或失调的方法。
• QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
  申请人：Gai Yonghua

  公开号：US20100003214A1

  公开（公告）日：2010-01-07

  The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY
  申请人：Yonezawa Shuji

  公开号：US20110237576A1

  公开（公告）日：2011-09-29

  The present invention provides a compound which has an effect of inhibiting amyloid-β production and is useful as a therapeutic agent for diseases induced by production, secretion and/or deposition of amyloid-β proteins. The present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein A is optionally substituted carbocyclic diyl or optionally substituted heterocyclic diyl; B is an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; R 1 is a group such as optionally substituted lower alkyl; R 2 is a group such as hydrogen; and R 3a and R 3b are each independently a group such as hydrogen, provided that the following compound is excluded.
• FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF
  申请人：PharmAkea, Inc.

  公开号：US20170369443A1

  公开（公告）日：2017-12-28

  Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
• US8324155B2
  申请人：——

  公开号：US8324155B2

  公开（公告）日：2012-12-04